Athersys, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
April 31, 2023 at 06:26 pm EDT
Share
Athersys, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported revenue was USD 0.032 million compared to USD 0.722 million a year ago. Net loss was USD 13 million compared to USD 21.71 million a year ago. Basic loss per share from continuing operations was USD 0.83 compared to USD 2.29 a year ago.
For the full year, revenue was USD 5.33 million compared to USD 5.51 million a year ago. Net loss was USD 72.54 million compared to USD 86.96 million a year ago. Basic loss per share from continuing operations was USD 6.07 compared to USD 9.69 a year ago.
Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company is engaged in the discovery and development of therapeutic product candidates to address unmet medical needs in multiple disease areas. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells are alternatively obtained from other tissue sources. It is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (MASTERS-2).
ATHERSYS, INC. 
